Galatea Bio
Galatea Bio is a CLIA-certified biotech that combines a diverse genomic biobank with proprietary AI algorithms for ancestry inference and polygenic risk scoring, serving biopharma, academic researchers, and clinicians focused on underrepresented populations.
- Company typePrivate
- Founded2021
- HeadquartersMiami Lakes, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Galatea Bio does
Galatea Bio is a Miami Lakes, Florida-based biotechnology company founded in 2021 that builds a diversified genomic data and clinical services platform aimed at populations historically underrepresented in genetic research. The company operates a CLIA-CMS certified, CAP-accredited high-complexity molecular diagnostics laboratory that offers clinical genetic testing for neurocognitive, immunological, and cardiovascular conditions, complemented by a CAP-accredited biobank providing biospecimen storage and sample retrieval under full chain of custody. Research sequencing services run on Illumina NovaSeq X Plus and Oxford Nanopore Promethion platforms, supporting WGS, WES, lpWGS, and long-read modalities.
The company's differentiator is its proprietary AI/ML stack applied to ancestry inference and polygenic risk scoring. Algorithms include Gnomix for high-resolution ancestry deconvolution, Neural ADMIXTURE (a neural-network autoencoder that reduces population genetics compute from approximately one month to hours), Archetypal Analysis for population clustering, and an ancestry-adjusted PRS (aaPRS) framework that personalizes model selection per individual and recalibrates for ancestry. These are wrapped into the StrataRisk™ SaaS platform launched in March 2025 and feed the Biobank of the Americas research initiative, which targets 10 million samples from diverse ancestries and currently claims access to 500K+ geno:pheno records with a 60%+ non-European diversity index.
Galatea generates revenue through four streams: clinical genetic testing (per-test reimbursement via a self-serve portal), biopharma R&D partnerships built around large-scale population sequencing consortiums with academic universities and health systems globally, biobanking services for research programs, and a growing platform/data-access layer including the new StrataRisk™ subscription SaaS. Pricing is quote-based and not publicly disclosed. Customer segments are biopharma/life sciences, academic and research institutions, healthcare providers, and health systems. Strategic partnerships with Stanford University, the Chan Zuckerberg Initiative, DNAnexus, Fabric Genomics, and Genetic Alliance's iHope network underpin both technology integration and sample acquisition. The company has raised approximately $33M-$45M across four rounds since 2021, with a $25M financing in March 2025 led by a 12-investor syndicate.
Galatea Bio firmographics
Firmographics- Name
- Galatea Bio
- Legal name
- Galatea Bio, Inc.
- Website
- https://galatea.bio
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Galatea Bio is a CLIA-certified biotech that combines a diverse genomic biobank with proprietary AI algorithms for ancestry inference and polygenic risk scoring, serving biopharma, academic researchers, and clinicians focused on underrepresented populations.
- Ownership category
- akta.pro rank
Galatea Bio industry classification
Industry- Product category
- Genomic Services & Precision Medicine
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industries
- Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Galatea Bio is headquartered
LocationHeadquarters
- HQ city
- Miami Lakes
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Galatea Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Clinical Testing & Genomic Services: CLIA-CMS certified, CAP-accredited molecular diagnostics laboratory offering genetic testing services to physicians and healthcare providers. Testing catalog empowers exploration of genetic variation for various diseases including neurocognitive, immunological, and cardiovascular conditions.
- Biopharma R&D Partnerships: Partnerships with pharmaceutical and life sciences organizations to build large-scale population sequencing programs in partnership with academic universities and health systems globally.
- Biobank Services: Biospecimen storage solutions, sample retrieval, and associated data storage services for research programs. CAP accredited biobank with storage at controlled temperatures and full chain of custody.
- Platform & Data Access: Access to genomic-phenotypic data lake and bioinformatics analysis platform for research and discovery purposes.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Galatea Bio product offering
Product offeringCore offering
Galatea Bio operates a CLIA-CMS certified and CAP-accredited high-complexity molecular diagnostics clinical laboratory providing clinical genetic testing and genomic services to physicians and healthcare providers. The company also offers research sequencing services using Illumina NovaSeq X Plus and Oxford Nanopore long-read platforms, CAP-accredited biobanking services, and the Biobank of the Americas research initiative, all powered by proprietary AI/ML algorithms for ancestry inference and ancestry-adjusted polygenic risk scoring.
Product overview
Galatea Bio is a biotechnology company offering an integrated platform of precision health products and services focused on genetic diversity. The core offerings include a CLIA-certified clinical testing laboratory providing molecular diagnostics and genomic services, research sequencing using Illumina and Oxford Nanopore platforms, and CAP-accredited biobanking with storage solutions. The platform integrates proprietary AI-powered bioinformatics including Ancestry Inference (Gnomix) and Ancestry-adjusted Polygenic Risk Scores (aaPRS), supported by the Biobank of the Americas research initiative. Recent product launches include StrataRisk™, a PRS SaaS platform for common disease risk assessment. Partnerships with DNAnexus and Fabric Genomics extend technical capabilities for cloud-based genomic analysis and integrated rare variant/PRS testing.
Differentiator
Problem solved
Functional benefit
Brands
- Biobank of the Americas: A Galatea-led research initiative that aims to build a global clinico-genomics database to facilitate diversity in association studies, polygenic and phenomic risk scoring models, and precision medicine implementations.
- StrataRisk™
Products and services
- Clinical Testing & Genomic Services Full-stack next-generation sequencing molecular diagnostics clinical laboratory and biobank (CLIA-CMS certified, CAP-accredited high-complexity lab) offering a testing catalog that empowers physicians to explore genetic variation and pathways of biological importance. Used by healthcare providers and physicians for clinical genetic testing and patient disease risk assessment.
- Research Sequencing Services Cost-effective sequencing services for research programs using Illumina NovaSeq X Plus (WGS, WES, WES+DP, lpWGS) and Oxford Nanopore long-read sequencing platforms from a CLIA/CAP lab. Enables participants to receive genetic incidental findings reports where protocol allows. Targeted at academic institutions and biopharma research programs.
- Biobanking Services CAP-accredited biobank offering storage solutions for biological specimens at controlled ambient temperatures (4-30-80-100°C) with redundant backup systems, automated temperature monitoring, sample retrieval with full chain of custody, and associated phenotypic/clinical data storage. Used by research programs and biopharma partners.
- Biobank of the Americas (BBofA) Galatea-led research initiative building a global clinico-genomics database to facilitate diversity in association studies, polygenic and phenomic risk scoring models, and precision medicine implementations. Develops custom disease-specific cohorts composed of diverse participants with associated healthcare record data, with a target of mapping genetic diversity of 10 million individuals.
- StrataRisk Polygenic Risk Score Platform Polygenic Risk Score (PRS) Software-as-a-Service (SaaS) platform designed to assess the polygenic contribution to common diseases such as cardiovascular, metabolic disorders, and cancer susceptibility. Used by healthcare providers and clinical laboratories to scale common disease risk assessment and reporting at population scale.
- Platform & Data Science Platform leveraging one of the largest private genomic-phenotypic data lakes (500K+ records, 60%+ non-European diversity) and a world-class team of population geneticists and bioinformatics experts. Provides biopharma and life sciences organizations access to large-scale population sequencing program consortiums in partnership with academic universities and health systems globally.
Companies that use Galatea Bio
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Galatea Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability9 records
Feature6 records
Galatea Bio partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Fabric GenomicscoreCollaboration to enhance and deliver comprehensive genetic testing for assessing individual susceptibility to common diseases. Integrates analysis of rare genetic variants and polygenic risk scoring (PRS) for broader risk assessment across populations of all ancestries.
- Genetic Alliance (iHope Genetic Health Program)coreGalatea joined the iHope Genetic Health (iGH) network to expand free genomic testing for underserved families worldwide. Partnership advances global health equity through precision medicine for communities historically underrepresented in genetic research.
- DNAnexuscorePartnership to advance precision medicine for underserved populations by integrating Galatea's diverse genomic datasets with DNAnexus' cloud platform. Aims to enhance access to advanced genetic tools, improving diagnostics, drug discovery, and health outcomes particularly in Latin America.
- Stanford UniversitycoreAcademic partnership providing access to latest technology in genetic research and analysis. Enables Galatea to stay at forefront of genetic research and leverage Stanford's research infrastructure.
- Chan Zuckerberg InitiativecoreStrategic partnership providing technology access and support for genetic research initiatives focused on underrepresented populations.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Galatea Bio competitors and assessment
Company assessmentDirect peers
- 23andMe: Consumer and clinical genetic testing platform with massive genotyped cohort and biopharma data licensing. Competes with Galatea in ancestry-aware genetic insights and pharma partnerships, though at vastly larger scale.
- Color Genomics: Clinical genetic testing company offering hereditary cancer and population health tests to providers and employers. Directly comparable CLIA-certified lab service model and biopharma-adjacent strategy.
- Helix: DNA sequencing platform operating a CLIA lab and population genomics programs with health systems. Directly comparable end-to-end sequencing-as-a-service and population health analytics approach.
- Genomic Prediction: Polygenic risk score company focused on embryo selection and disease risk assessment. Direct PRS-focused competitor with overlapping clinical genetic testing ambitions.
Broad incumbents
- Myriad Genetics: Established clinical genetic testing leader with deep payer relationships and broad hereditary disease and oncology menu. Competes in clinical testing market; ex-CSO Jerry Lanchbury is a Galatea scientific advisor.
- Natera: Public genetic testing company specializing in reproductive health and oncology. Competes in clinical genomics space and represents a scaled, well-capitalized reference for Galatea's CLIA-lab service model.
- Labcorp: Major clinical laboratory network offering extensive genetic and molecular diagnostics. Represents the consolidated incumbent against which Galatea must differentiate on diversity and PRS quality.
- Quest Diagnostics: Large reference lab with genetic and advanced diagnostics offerings. Competes broadly in clinical testing market with national logistics and payer contracts.
- deCODE genetics: Iceland-based population genetics pioneer (Amgen subsidiary) operating one of the world's most deeply phenotyped population biobanks. Comparable population-genomics + pharma-discovery model, though at far greater scale.
Emerging players
- Genomics plc: UK-based genomics company focused on polygenic risk scores for biopharma and health systems. Comparable PRS-led, biopharma-services business model with strong academic provenance.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Galatea Bio social profiles
Digital presenceGalatea Bio compliance and trust
Trust signalCompliance2 records
Galatea Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Galatea Bio leadership team
Management profileNumber of profiles
Profiles12 records
Galatea Bio funding detail
Funding detailFunding overview
Funding rounds4 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Galatea Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Galatea Bio
What does Galatea Bio do?
Galatea Bio operates a CLIA-CMS certified and CAP-accredited high-complexity molecular diagnostics clinical laboratory providing clinical genetic testing and genomic services to physicians and healthcare providers. The company also offers research sequencing services using Illumina NovaSeq X Plus and Oxford Nanopore long-read platforms, CAP-accredited biobanking services, and the Biobank of the Americas research initiative, all powered by proprietary AI/ML algorithms for ancestry inference and ancestry-adjusted polygenic risk scoring.
Is Galatea Bio a public or private company?
Galatea Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Galatea Bio founded?
Galatea Bio was founded in 2021. It employs 11 to 50 people.
Where is Galatea Bio based?
Galatea Bio is headquartered in Miami Lakes, United States, in the North America region.
How does Galatea Bio make money?
Four revenue lines are on record. Clinical Testing & Genomic Services are the primary driver. The others are biopharma R&D Partnerships, biobank Services and platform & Data Access.
Who are Galatea Bio's main competitors?
Direct peers on record are 23andMe, Color Genomics, Helix and Genomic Prediction. Broad incumbents are Myriad Genetics, Natera, Labcorp, Quest Diagnostics and deCODE genetics. Genomics plc is listed as an emerging player.
Does Galatea Bio have an API?
No public API is recorded for Galatea Bio.
What industry is Galatea Bio in?
Galatea Bio's product category is Genomic Services & Precision Medicine. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.